Anthropic’s $1.5 Trillion IPO Ambition and AI’s Medical Promise

By Nathan Brooks

Anthropic’s underwriters may raise the company’s IPO price range above $70 to $78, potentially lifting its valuation target to $1.5 trillion or more.

Goldman Sachs and Morgan Stanley lead the Anthropic (ANT) underwriters. The Financial Times reported that strong investor demand put the original range under review after Tuesday’s filing.

No final IPO price or completed offering was disclosed, so $1.5 trillion remains a scenario rather than an established market capitalization. The item attached no revenue, profit or capacity forecast to that valuation. Its separate $2 trillion reference was a joking aside, not the reported underwriter target.

How far does Anthropic’s medical forecast reach?

CEO Dario Amodei said: “You know, if today we look at things like cancer, Alzheimer’s, heart disease, mental illness, these will be relics of the past in, I think, less than a decade.”

Amodei also argued that, if humanity used artificial intelligence correctly, it could create an age of miracles in which people could solve problems that had defeated them for millennia.

That is a forecast from Anthropic’s chief executive, not a clinical finding or regulatory timetable. The report supplied no trial results, approval dates, treatment costs or implementation plan.

The contrast is brisk: an IPO price can reset on Tuesday; a medical forecast needs a decade. Until evidence narrows that gap, the medical claim belongs beside the IPO as a forward-looking proposition, not a commercial result.

What did CoreWeave do for AI-cloud stocks?

CoreWeave reported what the market roundup called a breakout quarter, and its strong guidance lifted five rival AI-cloud and neocloud stocks:

• Nebius (NBIS)
• IREN (IREN)
• Cipher Digital (CIFR)
• Applied Digital (APLD)
• Core Scientific (CORZ)

All five traded higher in active trading. That is a market read-through, not proof that their own contracts, capacity or earnings matched CoreWeave’s.

For semiconductor buyers, the omission is notable: the report gave no accelerator shipments, rack deployments, data-center capacity or pricing figures. The share moves therefore showed confidence in the direction of demand, not a disclosed unit forecast.

What does Rigetti’s quarterly miss reveal?

Rigetti Computing (RGTI) fell after third-quarter results fell short of expectations. The roundup nevertheless reported continued analyst optimism for the company’s long-term prospects.

StoneX Financial analyst Gary Mobley said: “gate-based quantum computers, such as those developed by RGTI, are years away from being commercial-grade and fault-tolerant, RGTI’s sales, bookings and RPOs will remain lumpy on a quarterly basis.”

His timeline is an analyst assessment, not a confirmed company schedule. It also explains why strong long-term sentiment and weak near-term revenue expectations can coexist without contradiction.

Why did Six Flags and Rivian move?

Six Flags Entertainment (FUN) rose after insider buying by its executive chairman, a director and its chief legal officer.

Jana Partners has joined a growing list of investors reportedly pressing for a sale. Shares remain down 28% this year. Insider buying is not a sale agreement, although the two developments clearly point in opposite directions.

Rivian received a different kind of endorsement. MotorTrend named the company’s R2 SUV its 2027 SUV of the Year, four years after the R1T pickup won Truck of the Year.

MotorTrend cited the R2’s clean, attractive, brand-affirming style, sensational driving dynamics, and enough luxury and utility to serve as a one-vehicle solution. It also called the vehicle something of a miracle.

That verdict arrives amid lackluster sales and what the report described as crippling cash burn at Rivian. An award does not repair a balance sheet by itself. The commercial test is whether the R2 converts attention into deliveries while cash burn persists.

A closing risk note said one or more securities discussed do not trade on a major U.S. exchange and carry associated risks.

For pricing and competition, watch whether Anthropic’s underwriters set a higher IPO band and whether CoreWeave’s guidance sustains the neocloud rally; Rigetti’s bookings will show whether quantum optimism has near-term commercial substance.